Y-Intercept (HK)
CTKB icon

Y-Intercept (HK)’s Cytek Biosciences CTKB Stock Holding History

Y-Intercept (HK)’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-193,128
Closed -$856K – 1666
2026
Q2 		$856K Buy
+193,128
New +$824K 0.02% 1108
2023
Q4 		– Sell
-19,234
Closed -$106K – 1295
2023
Q3 		$106K Buy
+19,234
New +$154K 0.01% 968

Other funds holding CTKB

Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
NorthCrest Asset Manangement
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Y-Intercept (HK)'s CTKB Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Cytek Biosciences (CTKB) in Q3 2026, closing a stake of 193,128 shares — an estimated $856K sold.

Y-Intercept (HK) first reported a position in CTKB in Q3 2023 and held it in 2 quarters. The position peaked at $856K in Q2 2026. 29 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Cytek Biosciences position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 193,128 Cytek Biosciences shares in Q3 2026, an estimated $856K.
  • Y-Intercept (HK) first reported a position in Cytek Biosciences in Q3 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Cytek Biosciences position peaked at $856K in Q2 2026.
  • 29 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.